iTheranostics, Novartis ink FAP-targeted drug development agreement
Sofie subsidiary iTheranostics has inked an agreement with Novartis to collaborat...Read more on AuntMinnie.comRelated Reading:
Novartis touts phase III prostate cancer study results
SNMMI celebrates 60th anniversary with special issue
Jubilant inks deal to invest $25M in Sofie
Novartis to buy Endocyte for $2.1B
SNMMI: Theranostic agent awarded Image of the Year
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news